drugset / Trial / NCT06679673
SHR-1701 Combined with SHR2554 and BP102 for MCRC
NaSingle-groupOpen-labelTreatment
Summary
Response to oncologic treatment in mCRC is currently limited.
Timeline
- Start
- 2024-12
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |
| Subject | SHR2554 | Small molecule | — | — |